Brain Behavior and Immunity Integrative, Год журнала: 2024, Номер 8, С. 100087 - 100087
Опубликована: Сен. 14, 2024
Язык: Английский
Journal of Psychoactive Drugs, Год журнала: 2024, Номер unknown, С. 1 - 10
Опубликована: Фев. 4, 2024
Qualitative studies and anecdotal reports suggest that experiences with ayahuasca, a psychedelic brew found in Central South America, may be followed by individuals enduringly feeling more grateful connected to nature. Yet, date, these changes have been understudied. Here, participants (N = 54) completed validated surveys related gratitude, nature relatedness, appreciation one-week before, after, one-month after attending an ayahuasca retreat center. Compared baseline, there was significant increase at the follow-ups. Ratings of mystical-type awe, but not ego dissolution, during participants' sessions were weakly-to-moderately correlated increases. The number ceremonies attended change outcomes, underscoring importance quality rather than quantity post-acute change. Lastly, participant age negatively occurrence supporting literature indicating blunted effects increased age. In context study limitations, results awe occasioned linked prosocial gratitude relationships beneficial mental health.
Язык: Английский
Процитировано
8
Journal of Psychoactive Drugs, Год журнала: 2025, Номер unknown, С. 1 - 11
Опубликована: Фев. 20, 2025
The durability of ayahuasca's effects on mental health and the influence clinical diagnoses therapeutic response is unclear. Adults with no prior exposure to ayahuasca (n = 66) participating in neo-shamanic ceremonies completed questionnaires at baseline, 7 days, 1, 6, 12 months. Mixed models were used characterize temporal trajectories health, alcohol cannabis use, affect, personality, spirituality, relationships examine longevity individuals without a depressive or anxiety disorder. After multiple comparison correction, use was associated decreases depression, anxiety, stress, negative emotionality, acceptance external influence, self-alienation all time points. Improvements self-efficacy, spirituality observed up months post-ceremony. Individuals depression maintained significant symptom reductions, whereas those diagnosis experienced short-term benefits. Decreases only month 1. Naturalistic persisting improvements wellbeing, largest magnitude reduction diagnosed Differing change identified across psychological constructs, suggestive both enhancement attenuation gains over time.
Язык: Английский
Процитировано
1
Psychiatry and Clinical Neurosciences Reports, Год журнала: 2023, Номер 2(4)
Опубликована: Окт. 2, 2023
Abstract Ayahuasca is a psychedelic plant brew originating from the Amazon rainforest. It formed two basic components, Banisteriopsis caapi vine and containing potent dimethyltryptamine (DMT), usually Psychotria viridis . Here we review history of ayahuasca describe recent work on its pharmacology, phenomenological responses, clinical applications. There has been significant increase in interest since turn millennium. Anecdotal evidence varies significantly, ranging evangelical accounts to horror stories involving physical psychological harm. The effects personality mental health outcomes are discussed this review. Furthermore, analyses experience explored. promising agent that warrants greater empirical attention regarding neurochemical mechanisms action potential therapeutic application.
Язык: Английский
Процитировано
15
Reference series in phytochemistry, Год журнала: 2024, Номер unknown, С. 1953 - 2005
Опубликована: Янв. 1, 2024
Язык: Английский
Процитировано
4
Biomolecules, Год журнала: 2024, Номер 14(9), С. 1128 - 1128
Опубликована: Сен. 6, 2024
For several decades, the dopamine hypothesis contributed to discovery of numerous typical and atypical antipsychotics was sole for pathophysiology schizophrenia. However, neither nor antipsychotics, other than clozapine, have been effective in addressing negative symptoms cognitive impairments, which are indices prognostic disability outcomes Following development therapeutic targets expanded beyond blockade D2 serotonin 5-HT2A receptors explore partial agonism receptor modulation new targets, such as D3, 5-HT1A, 5-HT7, metabotropic glutamate receptors. Despite these efforts, date, psychiatry has not successfully developed with antipsychotic properties proven be superior those clozapine. The hypothesis, another regarding pathophysiology/pathomechanism schizophrenia, proposed based on clinical findings that N-methyl-D-aspartate (NMDAR) antagonists, phencyclidine ketamine, induce schizophrenia-like psychotic episodes. Large-scale genome-wide association studies (GWASs) revealed approximately 30% risk genes schizophrenia (the total number over one hundred) encode proteins associated glutamatergic transmission. These supported validation inspired by NMDAR antagonists. Additionally, genetic suggest is possibly a syndrome complicated pathomechanisms affected multiple biological vulnerabilities. most extensively investigated hypothesis. Studies possibility functional abnormalities play important roles no derived from yet approved treatment or treatment-resistant Considering increasing evidence supporting potential pro-cognitive effects agents lack sufficient medications treat impairments previous setbacks cannot preclude research into novel modulators. Given this background, emphasize importance dysfunction pathomechanism and/or review introduces transmission NMDAR.
Язык: Английский
Процитировано
4
Clinical Pharmacology & Therapeutics, Год журнала: 2024, Номер unknown
Опубликована: Сен. 30, 2024
Psychedelics have recently re‐emerged as potential treatments for various psychiatric conditions that impose major public health costs and which current treatment options limited efficacy. At the same time, personalized medicine is increasingly being implemented in psychiatry to provide individualized drug dosing recommendations based on genetics. This review brings together these topics explore utility of pharmacogenomics (a key component medicine) psychedelic‐assisted therapies. We summarized literature explored implications genetic variability pharmacodynamics pharmacokinetics psychedelic drugs including lysergic acid diethylamide (LSD), psilocybin, N,N ‐dimethyltryptamine (DMT), 5‐methoxy‐ (5‐MeO‐DMT), ibogaine 3,4‐methylenedioxymethamphetamine (MDMA). Although existing evidence limited, particularly concerning pharmacodynamics, studies investigating indicate variants drug‐metabolizing enzymes, such cytochrome P450, impact intensity acute effects LSD ibogaine, a dose reduction CYP2D6 poor metabolizers may be appropriate. Furthermore, preclinical evidence, it can hypothesized metabolizer status might contribute altered experiences with 5‐MeO‐DMT psilocybin when combined monoamine oxidase inhibitors. In conclusion, considering early factors influence certain psychedelics, we suggest pharmacogenomic testing should further investigated clinical research. necessary evaluate its improving safety therapeutic profile therapies future role personalizing therapies, become available.
Язык: Английский
Процитировано
4
Psychedelic Medicine, Год журнала: 2025, Номер unknown
Опубликована: Фев. 3, 2025
Язык: Английский
Процитировано
0
Comprehensive analytical chemistry, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Psychoactives, Год журнала: 2025, Номер 4(2), С. 9 - 9
Опубликована: Апрель 1, 2025
Objective: To provide a state of the art on use, role, and function music during psychedelic-assisted therapy (PAT) with ayahuasca. Introduction: Ayahuasca is medicinal brew psychoactive qualities used by indigenous communities throughout Amazon region, deemed crucial ayahuasca experiences. In PAT, forms part set setting, but it lacks systematization poorly explored in scientific literature. Inclusion criteria: Published literature English, Spanish, Portuguese, focusing conceptualizing, defining, or describing and/or PAT sessions Methods: This review follows JBI methodology for scoping reviews. We will search Web Science, Scopus, Google Scholar, PubMed databases without year restrictions, hand articles be performed. Two reviewers assess titles/abstracts, followed independent reviews included full texts. An Excel data extraction sheet to tabulate information. The findings presented narratively, including respective tables figures. If feasible, potential theoretical framework outlined, implications future research clinical practice.
Язык: Английский
Процитировано
0
BMJ Open, Год журнала: 2025, Номер 15(4), С. e095992 - e095992
Опубликована: Апрель 1, 2025
Introduction Prolonged grief disorder (PGD) represents a substantial public health issue, especially in oncology settings where it affects up to 30% of bereaved carers. Current best-practice treatments are lengthy, and 50% participants have persistent PGD. Building on encouraging recent research with psychedelic-assisted therapies, the Psilocybin-Assisted suppoRtive psychoTherapy IN treatment prolonged Grief (PARTING) trial is first study consider psilocybin-assisted psychotherapy as potential for grief. Methods analysis PARTING an open-label pilot approximately 15 people cancer-related It aims investigate feasibility, safety, acceptability, participant experience participant-reported therapeutic effects. Over 5-week intervention period, will undergo three preparation sessions before receiving psychoactive (25 mg) dose psilocybin alongside non-directive supportive guidance, followed by four integration sessions. All be delivered psychologist either nurse or Indigenous Therapist. An artificial intelligence-assisted tool used create artwork participants’ psychedelic experience. Outcomes investigated over 12-month follow-up period. Feasibility assessed through recruitment/retention rates completion assessments. Safety evaluated via adverse events 12 months comparison physiological measures (vital signs, biochemistry, haematology, ECG) recorded during screening 1 day after dose. Qualitative thematic semistructured interviews therapists assess acceptability treatment. Diagnostic clinical PGD quantitative effects also being collected. Participant-reported include severity, depression, anxiety, avoidance, psychological flexibility, connectedness, quality life. Ethics dissemination approval has been obtained from QIMR Berghofer Medical Research Institute Human Committee (P3801). Dissemination results occur conference presentations, peer-reviewed publications media. Trial registration number Australian New Zealand Clinical Trials Registry (ACTRN12623000827639).
Язык: Английский
Процитировано
0